Moderna says COVID-19 vaccine safe and effective for teens, adolescents; will seek expanded FDA approval
Moderna today said its two-dose COVID-19 vaccine is safe and effective for individuals between 12 and 17 years old, citing data from its ongoing phase 2/3 clinical trial of 3,700 participants. Moderna reported a vaccine efficacy of 93% within 14 days of trial participants’ first dose, with zero reported cases of symptomatic COVID-19 two weeks after their final dose. Moderna said it will submit its data to the Food and Drug Administration in early June as part of a requested expansion of its emergency use authorization to include teens and adolescents.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…